OCILY19 cells were treated with 48nM gemcitabine for 3h and 5h (with 5h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.